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ABSTRACT. 
Background. Ankle-brachial index (ABI) is widely used to diagnose subclinical 
peripheral artery disease (PAD) in the general population, but data assessing its 
prevalence and related factors in different chronic kidney disease (CKD) stages are 
scarce. The aim of this study is to evaluate the prevalence and associated factors of 
pathologic ABI values in CKD patients. 
Methods. NEFRONA is a multicenter prospective project that included 2445 CKD 
patients from 81 centers and 559 non-CKD subjects from 9 primary care centers 
across Spain. A trained team collected clinical and laboratory data, performed vascular 
ultrasounds, and measured the ABI. 
Results. PAD prevalence was higher in CKD than in controls (28.0vs12.3%, p<0.001). 
Prevalence increased in more advanced CKD stages, due to more patients with an ABI 
≥1.4, rather than ≤0.9. Diabetes was the only factor predicting both pathologic values in 
all CKD stages. Age, female sex, carotid plaques, higher carotid intima-media 
thickness, higher high-sensitivity C reactive protein (hsCRP) and triglycerides and 
lower 25-hydroxi-vitamin D were independently associated to an ABI ≤0.9. Higher 
phosphate and hsCRP, lower LDL-cholesterol and dialysis were associated to an ABI 
≥1.4. A stratified analysis showed different associated factors in each CKD stage, 
being phosphate especially important in earlier CKD, and LDL-cholesterol an 
independent predictor only in stage 5D CKD. 
Conclusions. Asymptomatic PAD is very prevalent in all CKD stages, but factors 
related to a low or high pathologic ABI differ, revealing different pathogenic pathways. 
Diabetes, dyslipidemia, inflammation and mineral-bone disorders play a role in the 
appearance of PAD in CKD. 
 
Keywords: Ankle-brachial index; Atheromatosis; Cardiovascular risk; Chronic kidney 
disease; Peripheral artery disease. 
 
Summary. 
 Subclinical peripheral artery disease prevalence increases in more advanced 
CKD stages. Advanced CKD has a greater prevalence of high pathologic ABI, 
whereas earlier stages show more low pathologic ABI. 
 Factor related to low or high pathologic ABI are different. 
 Some factors, such as phosphate or cholesterol, exert different effects in 
different CKD stages. 
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Introduction 
Cardiovascular events (CVE) remain the main cause of mortality and morbidity in 
chronic kidney disease (CKD) [1]. This increase in cardiovascular complications is 
evident from the earliest CKD stages, even before a fall in glomerular filtration rate can 
be detected [2]. Recent guidelines and position statements have therefore defined CKD 
as a high cardiovascular risk condition [3]. 
In this sense, risk score charts fail to adequately recognize CKD patients at a higher 
cardiovascular risk, and the study of novel molecules to identify specific biomarkers is 
still undergoing [4-7]. These gaps may be due to a different pathogenesis of the 
atheromatous process in CKD, which has been described as an accelerated vascular 
ageing. For this reason, novel approaches for a suitable and reliable vascular 
assessment are urgently required in CKD patients. Those that detect atheromatosis in 
subclinical stages, such as vascular ultrasound, have shown promising results [8, 9]. 
Peripheral artery disease (PAD) is a frequent manifestation of atheromatosis, which 
can lead to intermittent claudication and surgical requirements. However, both in the 
general and the renal populations, it tends to be asymptomatic in earlier stages. One of 
the most widespread tests to diagnose subclinical PAD is the ankle-brachial index 
(ABI), which is the ratio between the highest humeral systolic blood pressure and the 
systolic blood pressure of the lower limbs. A normal ABI is around 1 or slightly higher, 
due to the effect of gravity on the vascular system in a standing position. An ABI value 
≤0.9 reflects a decrease in distal blood-flow, and several studies have proved it to be a 
good predictor for CVE [10-12]. Therefore, the test has is nowadays widely used in 
many clinical environments, including primary care (especially for high-risk subjects). 
Nevertheless, there are some controversies yet to be solved. On the one hand, the 
most appropriate method to measure the ABI. Vascular surgeons tend to use the 
“classical” method (highest value of systolic blood pressure of lower limbs), but a 
modified method was proposed by Schröeder et al. using the most pathologic value of 
all four obtained indexes. This is far more sensitive for CVE prediction [13, 14], and it is 
currently recommended for cardiovascular risk assessment [15]. Secondly, a high ABI 
value (≥1.3-1.4) has been considered not interpretable and disregarded in most studies 
because it does not allow assessment of the underlying blood flow. These values are 
due to vascular stiffness probably because of vessel wall calcification in the context of 
degenerative vascular ageing. However, some studies have shown that an ABI value 
≥1.4 is also associated to a worse cardiovascular prognosis, particularly when ischemia 
is superimposed [16-19]. 
On the other hand, data interpreting in depth the characteristics of pathologic ABI 
values in CKD are scarce, specifically comparing different CKD stages. Also, no 
studies have described subclinical PAD according to high or low pathologic ABI values 
in this population, despite the apparent important differences in pathogenesis and 
prognostic impact. The impact of mineral and bone metabolism disturbances (such as 
hyperparathyroidism and hyperphosphatemia) on cardiovascular disease and mortality 
is well known [20], but few studies have evaluated its relationship with the ABI in CKD 
[21, 22]. To the best of our knowledge, no study has analyzed this connection along the 
CKD spectrum. 
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The NEFRONA project is an observational multicenter prospective project designed to 
evaluate the prevalence and evolution of subclinical atheromatosis in CKD patients 
with no history of CVE, and the contribution of early diagnosis for a more precise risk 
assessment [23, 24]. The aim of the present study is to analyze the factors related to 
subclinical PAD in different CKD stages, and to distinguish those associated to a low or 
a high pathologic ABI. 
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Subjects and methods 
Study design 
NEFRONA is a prospective multicenter cohort project that enrolled 2445 CKD subjects 
in 81 Spanish hospitals and dialysis clinics, from October 2010 to June 2012. Patients 
were eligible if they fulfilled the following conditions: age between 18 and 74 years; and 
CKD stage 3 or higher as defined by current guidelines (glomerular filtration rate lower 
than 60 mL/min/1.73 m2 estimated using the 4-variable Modification of Diet in Renal 
Disease (MDRD) equation) [25]. Besides, 559 controls with an MDRD over 60 mL/ 
min/1.73 m2 were recruited from 9 primary care centers from different regions of the 
country. Exclusion criteria for both groups were active infections, pregnancy, life 
expectancy lower than 12 months, and history of CVE, carotid artery surgery or any 
organ transplantation.  
All patients signed an informed consent, and the study was approved by the Ethics 
Committee of the Arnau de Vilanova University Hospital. 
Study variables 
Information regarding the protocol for collecting clinical and laboratory data is specified 
in the baseline descriptive article [26]. Detailed information about methods used to 
evaluate subclinical atherosclerosis has also been published [24]. All vascular studies 
were performed with a standardized protocol by three experienced itinerant teams 
including a nurse and a radiology technician, who also recorded anthropometrical 
parameters and collected blood samples. 
All participants underwent a vascular ultrasound to measure carotid intima-media 
thickness and to evaluate the presence and characteristics of atheromatous plaques, 
following recommendations of the American Society of Echocardiography [27]. 
Common carotid intima-media thickness (CCIMT) was calculated as the mean value in 
right and left common carotid arteries (CCIMT). Plaque presence was evaluated in ten 
vascular territories of left and right sides (internal and common carotid arteries and 
carotid bulbs, and common and superficial femoral arteries). ABI was defined as the 
ratio between systolic blood pressure in posterior tibial or dorsalis pedis arteries, 
divided by the highest systolic blood pressure value of both brachial arteries, all of 
them detected with a continuous Doppler probe. The modified method was chosen for 
a higher sensitivity, selecting in each patient the most pathological of the four values 
[13]. A pathologic ABI was defined as a value ≤0.9 (diagnostic of limb ischemia) or ≥1.4 
(related to arterial incompressibility and stiffness, usually ascribed to vascular ageing 
degeneration). 
Statistical analysis 
Mean ± standard deviation was used to describe quantitative variables, while absolute 
and relative frequencies were used to describe qualitative data. When appropriate, 
continuous variables were categorized, either into dichotomous variables or into 
tertiles, searching for the optimal cut-off point using a Gini criterion. Fisher and Mann-
Whitney tests were performed to evaluate the association of clinical, anthropometrical, 
treatment-related and laboratory variables. Multiple logistic regression models were 
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used to predict pathologic ABI, using a stepwise algorithm with the Akaike’s criterion to 
determine the best combination of variables. Interactions were also considered in the 
multivariate models, and predicted probabilities were computed to graphically illustrate 
the effect of interactions. All statistical analyses were performed using the R package 
[28], and the threshold for significance was set at 0.05. 
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Results 
Mean age of the CKD population was 57.9±12.8 years, and 61.7% were male patients. 
Prevalence of hypertension, dyslipidemia and diabetes were 89.3%, 64.9% and 25.7% 
respectively. Mean CCIMT was 0.725 mm. The percentage of patients with 
atheromatous plaque was 70.1% (18.8% only in carotid arteries, 12.6% only in femoral 
arteries, and 38.7% in both sites). Detailed information on baseline characteristics of 
the patients has been previously published, and it has been summarized in 
Supplementary Table 1 [26]. 
CKD patients had a higher prevalence of subclinical PAD than non-CKD controls, both 
for pathologic low (28.0 vs 12.3%, p<0.001) and high values (11.0 vs 1.4%, p<0.001). 
More advanced CKD was associated to a lower prevalence of ABI ≤0.9 (19.8% in stage 
3, 16.9% in stages 4 and 5, and 13.4% in stage 5D, p=0.03), but to a clearly higher rate 
of ABI values ≥1.4 (5.6% in stage 3, 10.2% in stages 4 and 5, and 19.5% in stage 5D, 
p<0.001), as shown in Figure 1.  
Clinical, anthropometrical, treatment-related and laboratory variables were analyzed to 
evaluate their relationship to subclinical PAD. Table 1 shows the results of the 
multivariate logistic regression models to predict subclinical PAD in CKD patients, 
showing differences in factors related to pathologic low and high values. Main 
predictors of a low ABI were older age, female sex, diabetes, lower 25-hydroxi-vitamin 
D leves, higher high-sensitivity C reactive protein (hsCRP) and triglyceride levels, 
higher CCIMT and carotid plaque presence. An interaction between age and vascular 
plaques was found, showing that age only had a significant effect on ABI in subjects 
with carotid plaques (Figure 2A). On the other side, diabetes, higher hsCRP and 
phosphate levels, lower LDL-cholesterol levels and dialysis treatment predicted an ABI 
≥1.4. A very interesting interaction between serum phosphate and CKD stage was also 
found. Remarkably, serum phosphate exerts its maximum influence on vascular 
stiffness in earlier stages of renal impairment (Figure 2B). 
Given the significant association of CKD stage 5D with an ABI ≥1.4, a stratified 
multivariate analysis was performed (Table 2), uncovering that the influence of risk 
factors varies throughout the spectrum of CKD. Diabetes was the only factor that 
maintained its independent association through all CKD stages. In CKD stage 3, serum 
phosphate and lower LDL-cholesterol levels were independently associated to vascular 
stiffness. However, an interaction between LDL-cholesterol and serum albumin was 
found. In stages 4-5, diabetes and high hsCRP were the only significantly associated 
factors. Finally, in patients with stage 5D CKD, high hsCRP and low LDL-cholesterol 
levels predicted an ABI ≥1.4, with no interaction with albumin or other nutritional 
parameters. The effect of treatments for dyslipidemia was tested and disregarded.
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Discussion 
This study evaluates in depth the epidemiology of subclinical PAD and its related 
factors in a large CKD cohort. To the best of our knowledge, this is the first report 
assessing the prevalence of pathologic ABI along the continuum of CKD, making the 
specific distinction between values suggestive of ischemia and those related to 
vascular stiffness. 
As with many other cardiovascular conditions, peripheral artery disease is more 
prevalent in CKD patients than in non-CKD subjects, even in the earliest stages [29-
31]. However, it is initially asymptomatic, and it can only be diagnosed through 
screening tests, being the ABI the most extended one. An abnormal ABI is defined as 
≤0.9 or ≥1.4 in current guidelines [15], although a borderline ABI between 0.9 and 1.0 
has also been associated to a higher CVE rate [32]. In CKD and hemodialysis patients 
both low and high pathologic values have been linked to higher mortality rates [33, 34]. 
However, a low ABI value, associated to distal ischemia in the context of vessel 
atheromatosis, was related to calcification of main arteries, while a high ABI, due to 
non-compressibility of the artery, was related to calcification of peripheral distal arteries 
[34]. 
Given the differences in the pathogenesis and prognostic implications of the two 
possible different pathologic ABI values (≤0.9 or ≥1.4), a separate analysis was 
performed, revealing that factors associated to ischemia differ from those related to 
vascular stiffness. The analysis of factors related to the presence of an ABI ≤0.9 in 
CKD showed that most classical cardiovascular risk factors (diabetes, dyslipidemia, 
inflammation) are also related to subclinical vascular disease. These findings are in line 
with previously published evidence of subclinical PAD in CKD [35, 36], but we did not 
find a significant correlation with glomerular filtration rate as in other studies [37, 38]. 
Vitamin D deficiency has been linked to enhanced atherosclerosis in experimental 
models [39]. In our sample, lower vitamin D levels were independently associated to 
the presence of an ABI ≤0.9, a fact that has already been shown in general population 
[40, 41]. CCIMT thickening, which is believed to be an earlier stage of atheromatosis, 
was also independently related to the presence of an ABI ≤0.9, as a proof of the 
systemic condition of the atheromatous disease. Furthermore, a significant interaction 
between age and the presence of carotid atheromatous plaques was found regarding 
PAD prevalence prediction. Age has been shown to be the most powerful predictor for 
atheromatosis. However, there seems to be a subpopulation of patients protected from 
atheromatosis, whose probability of developing PAD is low regardless of their age, or 
even their renal function. Thus, age is not associated to a higher prevalence of ABI 
values ≤0.9 in patients free of plaque. Our group has found this age-dependent 
variation in other markers of atheromatosis, such as greater intima-media thickness or 
the presence of atheromatous plaques [42]. This finding reflects the importance of 
detecting atheromatous plaques for an adequate vascular risk assessment, since 
plaque-free patients also have a lower risk of PAD.  
Lower ABI values reflect a decrease in distal blood supply, while higher values result 
from vascular stiffness, which may or may not concur with distal ischemia. Although 
more tests would be necessary to ascertain blood flow, many studies have 
demonstrated that an ABI over the normal range is associated with poorer prognosis, 
9 
 
both in general and in renal populations [16, 43, 44]. More specific studies have also 
demonstrated that the coexistence of vascular stiffness with intravessel ischemia bears 
the worst prognosis [45]. Interestingly, the higher rate of PAD in more advanced CKD 
stages in this study is attributable to an increase in prevalence of ABI ≥1.4 at the 
expense of lower rates of ABI ≤0.9. This fact is consistent with the known increase in 
vascular calcification in renal disease, and its prognostic implications will require a 
more detailed evaluation. In our study, factors related to higher ABI values included 
higher hsCRP and, curiously, lower LDL-cholesterol levels, in a reverse 
epidemiological association already described and as a reflection to the nutritional 
status [46]. This anomalous effect of LDL-cholesterol on vascular prognosis has also 
been related to a potential confounding effect of inflammation (KraneV,2009). However, 
this is not the case as low cholesterol levels are still associated with pathological ABI 
independently of hsCRP. Another possible explanation could be that, althoug total LDL 
levels are lower, the proportion more pathogenic LDL subfractions or altered forms 
could be still higher in patients with pathological ABI (AsamiyaY,2013). Serum 
phosphate levels and CKD stage also predicted a high ABI, but with an interaction that 
revealed that the relationship is more evident in earlier CKD stages. 
It is interesting to overview the differences in factors associated to vascular stiffness 
according to the CKD stage. On the one side, diabetes was the only factor that 
remained related, regardless of CKD stage. It appears that factors related to subclinical 
PAD in stage 5D are similar to those associated to an ABI ≥1.4, being advanced CKD 
an intermediate situation. On the other side, as shown by the interaction, serum 
phosphate was only related to non-compressibility in earlier CKD. The impact of end-
stage renal disease on vascular calcification has been studied in detail. The 
contribution of higher serum phosphate levels both to the atheromatous and the 
vascular calcification processes is well known, both in the general and the renal 
population, although more strongly in the latter [22]. Phosphate levels have been 
formerly related not only to subclinical PAD [47, 48], but also to other markers of 
vascular damage [49, 50]. Other studies have previously described a distinct effect of 
hyperparathyroidism on an ABI suggestive of arterial stiffness [21]. Here, phosphate 
levels also seem to reveal a more advanced vascular damage, given its association to 
a higher ABI, which was more prevalent in stage 5D patients. However, this 
relationship was only significant in earlier stages, reinforcing the great importance of an 
early control of serum phosphate, maybe even within the high-normal range. The 
complexity of the effect of serum phosphate in different subpopulations has been 
evaluated in depth in the NEFRONA study, revealing different thresholds for men and 
women [51]. Finally, the impact of lower LDL-cholesterol was significant both in early 
and advanced CKD, regardless of hypolipidemic treatments. However, in stage 3 CKD 
it seems to be linked to other nutritional parameters, such as serum albumin (maybe 
associated to low-protein diets), while in stage 5D it remained as a single independent 
predictor. 
This study has some limitations. The first one is its cross-sectional nature. The analysis 
of long-term follow-up outcomes will reveal more information about the evolution of 
subclinical PAD in CKD patients, as well as the predictive value of the baseline ABI. 
The second one is the lack of a test to evaluate blood flow in patients with an ABI value 
≥1.4, such as the toe-brachial index.  
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In conclusion, subclinical PAD, diagnosed as a pathologic ABI, is more frequent in 
renal patients than in subjects with normal kidney function. Prevalence grows in more 
advanced CKD stages, at the expense of more patients with ABI ≥1.4, revealing more 
vascular stiffness. It is important to remark that there are differences in factors related 
to ischemic or to stiffness-related subclinical PAD, and between different CKD stages. 
The effect of some classic factors differ when evaluated altogether, presenting 
interesting variations, such as a subgroup of atheromatosis protected patients 
regardless of their age. Finally, there is a differential effect of serum phosphate and 
LDL-cholesterol in different CKD stages probably, related to nutritional parameters. 
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Table 1. Multivariate logistic regression to model subclinical PAD in CKD patients. 
 β (SE) OR 95% CI p-value 
ABI ≤0.9 vs 0.9<ABI<1.4     
   Intercept -3.10 (0.56) 0.04 0.01-0.13  
   Mean CCIMT 2.08 (0.54) 7.99 2.79-23.07 0.0001 
   Diabetes 0.64 (0.16) 1.91 1.40-2.59 0.00004 
   Sex (female) 0.64 (0.15) 1.90 1.42-2.55 0.00002 
   Triglycerides (102-155] vs <102 mg/dL) 0.30 (0.19) 1.36 0.93-1.98 0.11 
   Triglycerides >155 vs <102 mg/dL 0.56 (0.19) 1.74 1.21-2.53 0.003 
   hsCRP >6.9 mg/L 0.41 (0.17) 1.51 1.09-2.09 0.01 
   25-hydroxi-vitamin D ≤ 18.9 ng/L 0.66 (0.19) 1.93 1.34-2.83 0.0005 
   Age (per year) -0.03 (0.01) 0.97 0.95-0.99 0.002 
   Carotid plaque presence -3.58 (0.89) 0.03 0.00-0.16 0.00005 
   Interaction age*carotid plaque presence 0.07 (0.01) 1.07 1.04-1.10 <0.00001 
ABI ≥1.4 vs 0.9<ABI<1.4     
   Intercept -6.16 (1.31) 0.00 0.00-0.03  
   Diabetes 0.94 (0.19) 2.55 1.74-3.73 <0.00001 
   LDL-cholesterol >86 mg/dL -0.61 (0.18) 0.55 0.38-0.78 0.0008 
   hsCRP >6.9 mg/L 0.51 (0.19) 1.66 1.13-2.43 0.009 
   Serum phosphate (per mg/dL) 1.03 (0.36) 2.80 1.41-5.74 0.004 
   CKD stage 4-5 vs CKD stage 3 2.49 (1.52) 12.02 0.65-257.14 0.1 
   CKD stage 5D vs CKD stage 3 4.47 (1.39) 87.65 6.27-1479.06 0.001 
   Interaction serum phosphate*CKD stages 4-5 -0.65 (0.40) 0.52 0.23-1.13 0.1 
   Interaction serum phosphate*CKD stage 5D -0.94 (0.37) 0.39 0.19-0.79 0.01 
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PAD, peripheral artery disease; CKD, chronic kidney disease; SE, standard error; OR, odd 
ratio; CI, confidence interval; ABI, ankle-brachial index; CCIMT, common carotid intima-
media thickness; hsCRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein. 
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Table 2. Multivariate logistic regression to model an ABI ≥1.4 stratified by CKD stage. 
CKD stage Stage 3 Stages 4-5 Stage 5D 
 β (SE) OR 95% CI p-value β (SE) OR 95% CI p-value β (SE) OR 95% CI p-value 
Intercept -5.58 (1.01) 0.00 0.00-0.03  -2.72 (0.24) 0.07 0.04-0.10  -1.24 (0.21) 0.29 0.19-0.43  
Diabetes 1.07 (0.33) 2.93 1.54-5.57 0.001 1.45 (0.30) 4.24 2.37-7.72 <0.0001 0.64 (0.31) 1.90 1.02-3.47 0.04 
Serum phosphate (per mg/dL) 0.87 (0.27) 2.40 1.42-4.14 0.001         
hsCRP >6.9mg/L     0.76 (0.33) 2.13 1.10-4.03 0.02 0.70 (0.27) 2.02 1.19-3.41 0.009 
LDL-cholesterol >86 mg/dL -0.67 (0.34) 0.51 0.27-1.00 0.046     -0.62 (0.26) 0.54 0.33-0.89 0.02 
Albumin (per g/dL) 1.03 (0.74) 2.81 0.65-12.39 0.17         
Interaction LDL-cholesterol*albumin -1.89 (0.88) 0.15 0.03-0.86 0.03         
  
ABI, ankle-brachial index; CKD, chronic kidney disease; SE, standard error; OR, odd ratio; CI, confidence interval; hsCRP, high-sensitivity C reactive 
protein; LDL, low-density lipoprotein. 
16 
 
 
Legends to figures 
Fig. 1. Prevalence of pathological ABI values (≤0.9 or ≥1.4) in CKD vs non-CKD 
patients, and in different CKD stages. For CKD stages, a trend test was performed 
considering the stages as an ordinal variable. 
ABI, ankle-brachial index; CKD, chronic kidney disease. 
 
Fig. 2. Effect of the interaction between age and carotid atheromatosis for ABI ≤0.9 
prediction (A) and between serum phosphate and CKD stage for ABI ≥1.4 prediction 
(B). The lines represent prevalence (%), estimated from the corresponding logistic 
regression models including both the main effects and the interaction. The p-value 
assessing the statistical significance of the interaction is shown. 
ABI, ankle-brachial index; CKD, chronic kidney disease. 
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